S1P/S1P受体通路:炎症性肠病治疗新靶点的研究进展

S1P/S1P Receptor Pathway:A New Target for Treatment of Inflammatory Bowel Disease

目前,开发可以稳定治疗炎症性肠病(IBD)的靶向口服药物仍是一个临床待解决的难题。近年来有研究证实,鞘氨醇-1-磷酸(S1P)/S1P受体通路可以调节淋巴细胞归巢和免疫调控,抑制肠道炎症,保护肠道内皮屏障,并对肠道微生物代谢产生影响,可能在IBD治疗中发挥关键作用。本文就S1P/S1P受体通路对IBD的影响及其潜在的作用机制作一综述。

The development of targeted oral drugs that can stably treat inflammatory bowel disease(IBD)is still a clinical problem to be solved.In recent years,studies have confirmed that sphingosine-1-phosphate(S1P)/S1P receptor pathway can regulate lymphocyte homing and immune regulation,inhibit intestinal inflammation,protect intestinal endothelial barrier,and affect intestinal microbial metabolism,which may play a key role in the treatment of IBD.This article reviewed the effect of S1P/S1P receptor pathway on IBD and its potential mechanism.